Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

abolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States, subject to FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the termination of Arena's collaboration with Ortho-McNeil-Janssen and related expectations and future activities; the therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of APD597 alone and in combination; the potential of GPR119; Arena's GPR119 patent portfolio and program and potential opportunities; the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the risk that APD597 or GPR119 agonists as a class may not realize their potential or ever receive marketing approval; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner and/or the information
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics Corporation ... ActiPatch® Musculoskeletal Pain Therapy medical devices, announced today ... its ActiPatch 7-day trial device has been published ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than ... and submitted an assessment.  Chronic ...
(Date:8/4/2015)... KNOXVILLE, Tenn., Aug. 4, 2015 Second ... million; 30.1% over second quarter of 2014 , Net ... $28.9 million; $51.2 million after adjustments , Diluted net ... , Adjusted EBITDA increased 15.2% to $99.4 million ... increased to a range of 24.0% to 26.0%; Adjusted EBITDA ...
(Date:8/4/2015)... Minn., Aug. 4, 2015 ANI Pharmaceuticals, Inc. ... for the three and six months ended June 30, ... Company will host its earnings conference call this morning, ... other interested parties can join the call by dialing ... Year-to-Date Highlights Include: , Year-to-date net revenues of ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3
... International Holdings, Inc. (NYSE Amex: BONE ... bone graft material and antimicrobial coatings for medical ... three-year agreement with Novation, a leading health care ... provides Bacterin,s full biologic portfolio, including OsteoSponge®, OsteoSelect® ...
... Fla., May 8, 2012 Grappling with economic uncertainty, ... industry is on the cusp of major changes, said ... opening session of the 2012 GHX Healthcare Supply Chain ... GPOs and distributors gathered this week in Orlando for ...
Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 2GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Many men ... on the subject, Renew Man™ is standing up as a voice of authority for ... of the healthy aging industry with special experience and expertise in the safe and ...
(Date:8/4/2015)... ... ... 24/7 Care At Home , a provider of comprehensive home health ... the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating of ... the path to meeting the aspirational goals the VA promotes each year. , ...
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... firms and government entities, today announced that John Munro, a 15-year veteran of ... President of Managed Services Operations. , “I am thrilled to join Discovia at ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... conducted by the anthropologists, from the University of Connecticut, University ... , ,They said that Neanderthals were very good in hunting ... modern humans. ,But the early modern humans ... due to the competition they received from the early modern ...
... by scientists belonging to the Northwestern University targeted at ... //The gene therapy, described in the January online issue ... Bohn and her laboratory group at Northwestern University Feinberg ... Medical Research Council Professor and director of the neurobiology ...
... on the rise and is rapidly becoming the number one cancer ... seriousness of the situation is apparent after going through recent data ... ,The rise is being documented mainly in the metros, but it ... unnoticed. It is reported that one in 22 women in India ...
... more than a couple of seconds to decide whether the ... findings. The decision is often taken in less than a ... impossible to really see anything in less than 500 milliseconds,’ ... has published the research in the journal Behavior and Information ...
... improvements made in diagnoses and treatment of the fatal ... a cure rate of 90%, according to researchers belonging ... ,The progressive improvement in the cure rate since ... reflects in large part the more effective use of ...
... to medical science, doctors under the leadership of Dr Hasan ... would perform surgery on patients while they// are in a ... out from their bodies while the surgery is being performed ... is complete. ,The return of blood would be ...
Cached Medicine News:Health News:Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate 2
... Sensor is the first sensor designed specifically ... sensor is the first and only sensor ... and children. Cyanotic infants and children ... and accurate pulse oximetry, and Masimo's research ...
ELISA kit for Varicella-zoster IgG detection....
... Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to VZV in ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
Inquire...
Medicine Products: